J 2019

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

MIRAVITLLES, Marc, Vladimir KOBLIZEK, Cristina ESQUINAS, Branislava MILENKOVIC, Adam BARCZYK et. al.

Basic information

Original name

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

Authors

MIRAVITLLES, Marc (724 Spain, guarantor), Vladimir KOBLIZEK (203 Czech Republic), Cristina ESQUINAS (724 Spain), Branislava MILENKOVIC (688 Serbia), Adam BARCZYK (616 Poland), Ruzena TKACOVA (703 Slovakia), Attila SOMFAY (348 Hungary), Kirill ZYKOV (643 Russian Federation), Neven TUDORIC (191 Croatia), Kosta KOSTOV (100 Bulgaria), Zuzana ZBOŽÍNKOVÁ (203 Czech Republic, belonging to the institution), Michal SVOBODA (203 Czech Republic, belonging to the institution), Jurij SORLI (705 Slovenia), Alvils KRAMS (428 Latvia) and Arschang VALIPOUR (40 Austria)

Edition

RESPIRATORY MEDICINE, LONDON, W B SAUNDERS CO LTD, 2019, 0954-6111

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.095

RIV identification code

RIV/00216224:14110/19:00110576

Organization unit

Faculty of Medicine

UT WoS

000463627700022

Keywords in English

COPD; CAT; mMRC; Comorbidities; GOLD classification

Tags

Tags

International impact, Reviewed
Změněno: 4/9/2019 15:03, Mgr. Tereza Miškechová

Abstract

V originále

Background: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. Methods: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. Results: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. Conclusions: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT > 10 is not equivalent to mMRC > 2 for assessing symptom burden.